يعرض 1 - 1 نتائج من 1 نتيجة بحث عن '"Alexander Pecheniy"', وقت الاستعلام: 1.59s تنقيح النتائج
  1. 1
    FAST: An international, multicenter, randomized, phase II trial of epirubicin, oxaliplatin, and capecitabine (EOX) with or without IMAB362, a first-in-class anti-CLDN18.2 antibody, as first-line therapy in patients with advanced CLDN18.2+ gastric and gastroesophageal junction (GEJ) adenocarcinoma

    المؤلفون: Marina Nechaeva, Assen Dudov, Martin Schuler, Salah-Eddin Al-Batran, Zanete Zvirbule, Ugur Sahin, Christoph Huber, Yuriy Vynnyk, Andriy Rusyn, Natalia Fadeeva, Florian Lordick, Igor Bondarenko, Igor Bazin, Ihor Vynnychenko, Georgiy Manikhas, Christian Mueller, Alexander Pecheniy, Ö. Türeci, Evgeny Gotovkin, Bohuslav Melichar

    المصدر: Journal of Clinical Oncology. 34:LBA4001-LBA4001

    مصطلحات موضوعية: 0301 basic medicine, Oncology, Cancer Research, medicine.medical_specialty, biology, business.industry, Cancer, medicine.disease, Oxaliplatin, Capecitabine, 03 medical and health sciences, 030104 developmental biology, 0302 clinical medicine, Trastuzumab, 030220 oncology & carcinogenesis, Internal medicine, Cancer cell, biology.protein, Medicine, Adenocarcinoma, Antibody, business, medicine.drug, Epirubicin

    URL الوصول: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6e2f9f7babf7a4da78ea88a25a470619
    https://doi.org/10.1200/jco.2016.34.18_suppl.lba4001

    أضف إلى المفضلة
أدوات البحث: أحصل على تغذية RSS – أرسل هذا البحث بالبريد الإلكتروني – حفظ البحث – جدول التنبيهات: لا شيء